ArticleCureus2026
A Prospective Study of Clinical Presentation, Radiological Findings, and Treatment Outcomes in Patients With Idiopathic Granulomatous Mastitis at a Single Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic granulomatous mastitis (IGM) is a benign, inflammatory breast disease that clinically and radiologically mimics malignancy and infection, posing diagnostic and therapeutic challenges - particularly in tuberculosis (TB)-endemic settings. Evidence on standardized, medical-first strategies in Indian cohorts remains limited.
objectiveTo describe the clinical presentation, radiological features, histopathology, and treatment outcomes of IGM managed with corticosteroids, methotrexate (MTX), and hydroxychloroquine (HCQ) at a single center.
methodsIn this prospective cohort (October 2016-June 2025), consecutive patients with core biopsy-confirmed IGM were enrolled after exclusion of infection (including TB polymerase chain reaction (PCR)/culture), autoimmune diseases, and systemic granulomatous disorders. Clinical, laboratory, and multimodality imaging (ultrasonography (USG) and mammography for all; MRI selectively) were recorded. Patients received tapering oral corticosteroids (0.5 mg/kg/day) and upfront MTX (10-15 mg/week); HCQ was added in selected cases. Follow-up included monthly, then three‑monthly assessments with serial labs and imaging. Outcomes were analyzed descriptively.
resultsWe identified 110 women (mean age 37.7 ± 7.4 years). Common presentations were breast swelling (41.8%, n=46), palpable lump (30.9%, n=34), pain (22.7%, n=25), and discharge (8.2%, n=9). Imaging typically showed ill‑defined, heterogeneous hypoechoic masses with frequent abscesses, sinus tracts, and reactive axillary nodes; Breast Imaging Reporting and Data System (BI‑RADS) categories were 2 (n=15), 3 (n=29), and 4A-4C (n=66). Histopathology most often demonstrated IGM (48.6%, n=54) and cystic neutrophilic granulomatous mastitis (CNGM; 23.9%, n=26). All patients received corticosteroids plus MTX; most did not require surgery. By 12 months, 76% (n=76) showed clinical improvement on MTX monotherapy; among 100 patients with 12‑month data, 38% (n=38) had no evidence of disease, 56% (n=56) continued treatment, 7% (n=7) were lost to follow‑up, and 9% (n=9) had no improvement. At 18 months, overall, recurrence was documented in nine patients; no clinically significant adverse events were recorded. Median treatment duration was 18-24 months.
conclusionsIn this Indian single‑center prospective cohort, a medical‑first strategy using corticosteroids with early MTX achieved high rates of improvement, low surgical utilization, and acceptable recurrence. Multimodality imaging often necessitated biopsy due to frequent BI‑RADS 4 assignments. These findings support conservative, immunomodulator‑based management and underscore the need for standardized protocols and multicenter prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.